{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-methylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-methylamine
• 英文别名: 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-2-methylpropan-1-amine
• 化学式: C₁₆H₁₆Cl₂FNO
• 分子量: 328.214
• InChiKey: QRAGHLLVBYVVPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
  申请人：Pfizer Inc.

  公开号：US20020123490A1

  公开（公告）日：2002-09-05

  The present invention relates to a method of treating depression, obsessive compulsive disorder and psychosis in a mammal, including a human, by administering to the mammal an atypical antipsychotic in combination with an antidepressant agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, an atypical antipsychotic, and an SRI.

  本发明涉及一种治疗哺乳动物，包括人类，的抑郁症、强迫症和精神病的方法，通过向哺乳动物投予一种非典型抗精神病药物与抗抑郁药物的组合，以提高效率。它还涉及含有一种药学上可接受的载体、一种非典型抗精神病药物和一种SRI的药物组合。
• Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
  申请人：Pfizer Inc.

  公开号：US20020147206A1

  公开（公告）日：2002-10-10

  The present invention relates to a method of treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal by administering to the mammal a neurotransmitter-inducing or precursor agent in combination with an (SRI) antidepressant or an anxiolytic agent with improvement in efficiency. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a neurotransmitter-inducing or precursor agent, and an SRI antidepressant or anxiolytic agent.

  本发明涉及一种治疗哺乳动物中多发性硬化症、其他脱髓鞘性疾病和外周神经病变的方法，该方法通过向哺乳动物投与一种神经递质诱导或前体药物，结合(SRI)抗抑郁药物或抗焦虑药物，以提高效率。还涉及含有药学上可接受的载体、神经递质诱导或前体药物以及SRI抗抑郁药物或抗焦虑药物的药物组合物。
• Combination treatment for depression
  申请人：——

  公开号：US20020107244A1

  公开（公告）日：2002-08-08

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with an SRI antidepressant agent with improvement in sexual function and/or reduction in gastro-intestinal side effects. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant.

  本发明涉及一种治疗哺乳动物，包括人类的抑郁症或焦虑症的方法，通过给哺乳动物同时注射5-HT3受体拮抗剂和SRI抗抑郁剂来改善性功能和/或减少胃肠道副作用。它还涉及含有药用载体、5-HT3受体拮抗剂和SRI抗抑郁剂的制药组合物。
• Combination treatment for sleep disorders including sleep apnea
  申请人：Pfizer Inc.

  公开号：US20020183306A1

  公开（公告）日：2002-12-05

  The present invention relates to a method of treating sleep disorders including sleep apnea in a mammal, including a human, by administering to the mammal a 5HT1a antagonist or an alpha-2-adrenergic antagonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT1a antagonist or an alpha-2-adrenergic antagonist, and an SRI antidepressant agent.

  本发明涉及一种治疗哺乳动物（包括人类）的睡眠障碍，包括睡眠呼吸暂停的方法，通过给哺乳动物（包括人类）施用5HT1a拮抗剂或α-2肾上腺素受体拮抗剂与SRI抗抑郁药物的联合使用，以提高疗效。本发明还涉及含有药用载体、5HT1a拮抗剂或α-2肾上腺素受体拮抗剂和SRI抗抑郁药物的制药组合物。
• Combination treatment for anxiety and depression
  申请人：Pfizer Inc.

  公开号：US20020165217A1

  公开（公告）日：2002-11-07

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a GABA-A alpha ⅔ agonist in combination with an SRI antidepressant agent with improvement in efficacy. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a GABA-A alpha ⅔ agonist, and an SRI antidepressant agent.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁症或焦虑症的方法，通过给哺乳动物（包括人类）以GABA-A alpha ⅔ 激动剂和SRI抗抑郁剂的联合使用以提高疗效。同时，本发明还涉及含有药学上可接受载体、GABA-A alpha ⅔ 激动剂和SRI抗抑郁剂的制药组合物。